A phase I b clinical trial (NCT06616636) evaluating PC14586 in combination with azacitidine for TP53 Y220C-mutant myeloid M = malignancies (acute myeloid leukemia or myelodysplastic syndromes) is currently enrolling participants, with clinical outcomes yet to be reported. This evidence concerns the gene TP53 and myelodysplastic syndrome.